Mistrust, costs reduce breast cancer screening among minorities

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

Negative perceptions and tough economic times keep women away from screening programs, but self-examination still highly rated.

Negative perceptions and tough economic times keep women away from screening programs, but self-examination still highly rated.

CAREFREE, ARIZ.-Distrust of healthcare providers, cultural barriers, lack of information about the benefits of screening, or simply the need to cut corners might all contribute to the levels of compliance for breast cancer screening among minorities, including African Americans and Hispanics, according to research presented at the 2009 AACR Conference on the Science of Cancer Health Disparities.

In one of the studies, a group from Michigan State University in East Lansing found that more than two-thirds of minority women believe that healthcare organizations sometimes mislead or even purposely deceive patients.

This perception, among a series of other factors, may be preventing these women from getting breast cancer screenings, said principal investigator Karen Patricia Williams, PhD, an assistant professor of ob/gyn and reproductive biology at the university’s College of Human Medicine.

Based on interviews with 341 women, Dr. Williams and colleagues found that 39% of African-American women expressed distrust. About 15% of Latinas and 9% of Arab-American women said they were suspicious.

Nearly half of all women in the study who had never undergone mammography screening said they believe medical organizations have experimented on patients without their knowledge. And almost two-thirds of women who had not received a breast exam in the last year agreed they are not sure if care providers really know what they are doing. Another significant finding of the study was that many minority women will use health services only when they are sick.

In a separate study involving 317 Mexican-American women from the ELLA Binational Breast Cancer Study, University of Arizona researchers determined that 68% of breast cancers in Hispanic women were self-detected. Although screening mammography rates were high for U.S.-born (85%) and foreign-born women (63%), only 22% of cancers were mammography detected and 6% were physician detected through a clinical exam.

Half (51%) of the women with breast cancer waited at least one month before seeking medical attention, said study author Rachel Zenuk, a graduate student at the University of Arizona Cancer Center in Tucson. Delaying medical care was associated with a lack of health insurance (31%) and not feeling it was important (33%).

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.